More possible drug options for Multiple Myeloma Patients

April 30, 2012 08:30 AM Eastern Daylight Time

A New Drug Used by 71-Year-Old Marathoner DonWright Could Soon Be Approved to Help More Patients with Multiple Myeloma Says Tackle Cancer Foundation

Pomalidomide from Celgene has been Submitted to the FDA for Approval

DALLAS–(BUSINESS WIRE)–Leaders of the Tackle Cancer Foundation (TCF) today said they are excited to learn that a new drug for patients with multiple myeloma, pomalidomide from CELGENE, has been submitted to the Food and Drug Administration. If approved it would mean patients with the bone marrow cancer multiple myeloma would have access to this potent new drug without going into a clinical trial.

“We are proud that Elijah did his part to help bring new drugs toward approval, and we are sure he would be pleased to know that soon patients may have a new option. We eagerly await the FDA decision.”

Don Wright, the 71-year-old marathon runner sponsored by TCF in the E-Race Cancer Campaign, takes pomalidomide for his multiple myeloma. Taking an oral drug without the side effects of typical chemotherapy allows him to continue with his personal passion, running marathons. Don hopes to complete marathons in all 50 US states this year, nine years after he was first diagnosed with cancer. But Don Wright must depend on a clinical trial to get his pomalidomide.

“We know from personal experience that it is essential for cancer patients to have ready access to new therapies,” said Kimberly Alexander, TCF Executive Director. “When our founder, my late husband Elijah Alexander, had gone through all of the available therapies, he had to travel out of state to get into a clinical study so he could get new treatments. But not every patient can do that, and no patient should have to.”

Elijah Alexander, a former NFL football player was diagnosed with multiple myeloma at age 35, much younger than the typical patient profile. His first treatment, a bone marrow transplant, left him weak and debilitated. When a new drug called REVLIMID® became available, he got his strength back, and started the Tackle Cancer Foundation to support myeloma research and help families who have a child with cancer.

Elijah experienced the benefits of new drug development first hand. But multiple myeloma cannot be cured, remissions end, and patients need new options. Elijah had been through all of the available drugs and Kimberly notes that he had to find a clinical trial so he could continue treatments.

“We are proud that Elijah did his part to help bring new drugs toward approval, and we are sure he would be pleased to know that soon patients may have a new option. We eagerly await the FDA decision.”

The Tackle Cancer Foundation helps pay family utility bills up to $2500 per year. A portion of the proceeds goes to the International Myeloma Foundation for research.

More information about TCF can be found at www.tacklecancerfoundation.org.

Information about E-Race Cancer is available at www.facebook.com/ERACECANCER.

 

Contacts

For TCF
Peggy C. Frank, 818-735-3591
pfrank@frankpr.com

Comments are closed.